Biomarkers for chronic fatigue syndrome and long covid and uses thereof
AssigneeBristol-Myers Squibb Company
InventorsSarah Ann HERSEY, Zheng WANG, Tara Joy BASAVANHALLY, Gonzalo LOPEZ GARCIA, Yixin WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and kits using certain biomarkers in predicting and monitoring post-viral syndromes (for instance, chronic fatigue syndrome (CFS) and/or long CO VID), selectively treating such syndromes, and assessing clinical sensitivity and therapeutic response to treatments. Wherein determining an expression level of a biomarker in a sample from the subject is disclosed.
Claims67
A method of identifying a subject having Chronic Fatigue Syndrome (CFS) or verifying CFS in a subject, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- and
- (b) identifying or verifying the subject as having CFS if the expression level of the biomarker is higher than a reference expression level of the biomarker.
A method of determining severity of CFS in a subject, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- (b) comparing the expression level of the biomarker with a reference expression level of the biomarker;
- and
- (c) determining the severity of CFS in the subject based on the comparison in step (b).
A method of identifying a subject who is likely or not likely to be responsive to a treatment of CFS or predicting the responsiveness of a subject to a treatment of CFS, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- and
- (b) identifying or predicting the subject as being likely to be responsive to the treatment if the expression level of the biomarker is higher than a reference expression level of the biomarker.
A method of selectively treating a subject having or suspected of having CFS with a treatment, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- (b) identifying or predicting the subject as being likely to be responsive to the treatment of CFS if the expression level of the biomarker is higher than a reference expression level of the biomarker;
- and
- (c) administering the treatment to the subject identified or predicted to be likely to be responsive to the treatment.
A method of determining or monitoring effectiveness of a treatment in a subject having CFS, the method comprising:
- (a) determining a first expression level of a biomarker in a first sample obtained from the subject before administering the treatment to the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- (b) administering the treatment to the subject;
- (c) determining a second expression level of the biomarker in a second sample obtained from the subject after administering the treatment to the subject;
- and
- (d) determining the effectiveness of the treatment based on the comparison of the first expression level with the second expression level.
A method of screening a treatment for effectiveness in treating CFS, the method comprising:
- (a) determining a first expression level of a biomarker in a sample before administering the treatment to the sample, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, ABCE1, IKZF2, IKZF3, BACH2 and CD3D;
- (b) administering the treatment to the sample;
- (c) determining a second expression level of the biomarker in the sample after administering the treatment to the sample;
- (d) comparing the first expression level with the second expression level;
- and
- (e) selecting the treatment if the second expression level is lower than the first expression level.
A method of identifying a subject having long COVID or verifying long COVID in a subject, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, IKZF3, ABCE1, IKZF2, BACH2 and CD3D;
- and
- (b) identifying or verifying the subject as having long COVID if the expression level of the biomarker is higher than a reference expression level of the biomarker.
A method of identifying a subject who is likely or not likely to be responsive to a treatment of long COVID or predicting the responsiveness of a subject to a treatment of long COVID, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, IKZF3, ABCE1, IKZF2, BACH2 and CD3D;
- and
- (b) identifying or predicting the subject as being likely to be responsive to the treatment if the expression level of the biomarker is higher than a reference expression level of the biomarker.
A method of selectively treating a subject having or suspected of having long COVID with a treatment, the method comprising:
- (a) determining an expression level of a biomarker in a sample from the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, IKZF3, ABCE1, IKZF2, BACH2 and CD3D;
- (b) identifying or predicting the subject as being likely to be responsive to a treatment of long COVID if the expression level of the biomarker is higher than a reference expression level of the biomarker;
- and
- (c) administering the treatment to the subject identified or predicted to be likely to be responsive to the treatment.
A method of determining or monitoring effectiveness of a treatment in a subject having long COVID, the method comprising:
- (a) determining a first expression level of a biomarker in a first sample obtained from the subject before administering the treatment to the subject, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, IKZF3, ABCE1, IKZF2, BACH2 and CD3D;
- (b) administering the treatment to the subject;
- (c) determining a second expression level of the biomarker in a second sample obtained from the subject after administering the treatment to the subject;
- and
- (d) determining the effectiveness of the treatment based on the comparison of the first expression level with the second expression level.
A method of screening a treatment for effectiveness in treating long COVID, the method comprising:
- (a) determining a first expression level of a biomarker in a sample before administering the treatment to the sample, wherein the biomarker is a cereblon (CRBN)-associated protein (CAP) selected from the group consisting of HSPA8, IKZF3, ABCE1, IKZF2, BACH2 and CD3D;
- (b) administering the treatment to the sample;
- (c) determining a second expression level of the biomarker in the sample after administering the treatment to the sample;
- (d) comparing the first expression level with the second expression level;
- and
- (e) selecting the treatment if the second expression level is lower than the first expression level.
Dependencies are inferred from the claim text.